Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 10
Chunk 0
---
Executive Officers and Directors 

The following table sets forth the persons who serve as our executive officers and directors, and their ages as of March 31, 2025: 

    Name
     
    Age
     
    Position(s)

    Executive Officers

    James Bianco, M.D.
     
    68
     
    Chief Executive Officer and Director 

    Dan Dearborn
     
    58
     
    Chief Financial Officer

    Non-Employee Directors

    James Manuso, Ph.D., MBA
     
    76
     
    Director and Chairman of the Board

    Alan List, M.D.
     
    70
     
    Director 

    George Ng
     
    51
     
    Director

    Robert E. Hoffman
     
    59
     
    Director

    Craig Tendler, M.D.
     
    66
     
    Director

Executive Officers

James Bianco, M.D. has served as our Chief Executive Officer and as a director since the completion of the Kintara Merger and for Legacy TuHURA since July 1, 2021. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of Morphogenesis Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to us. Dr. Bianco is a 30-year veteran of the biopharmaceutical industry. In 1991, Dr. Bianco founded CTI Biopharma, Inc. (“CTI”) and from 1992 to 2016 was the Chief Executive Officer of CTI. During his tenure at CTI, Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three receiving accelerated or conditional regulatory approval in the U.S. and/or E.U. 

Dr. Bianco earned his M.D. from the Mount Sinai Icahn School of Medicine and completed his residency and chief residency at the Mount Sinai Medical Center in New York City. He completed his fellowship in Hematology/Oncology at the University of Washington/Fred Hutchinson Cancer Research Center (FHCRC) where he was appointed Assistant Professor of Medicine, Assistant Member FHCRC and Director of the Bone Marrow Transplant Unit at a “